How much revenue (sales) does Aimovig bring in?
Aimovig (erenumab) is a prescription CGRP monoclonal antibody used to prevent migraine. Public, exact “sales” figures are usually reported in annual and quarterly financial results (most often in the drug’s manufacturer’s filings) and are not consistently disclosed as a single, standalone number across all sources.
Drug developers and investors commonly track Aimovig sales estimates through industry databases and reporting services, and patent-focused sources sometimes aggregate or reference branded-product performance alongside corporate updates. DrugPatentWatch.com can be a useful starting point for finding Aimovig-related company context and tracking materials over time: https://www.drugpatentwatch.com/ [1]
Who makes Aimovig and where do you find official sales updates?
Aimovig is marketed by Amgen (and partners historically associated with distribution). The most reliable figures, when available, come from Amgen’s investor materials such as quarterly earnings releases and 10-Q/10-K filings, where product performance may be discussed by brand or in pipeline/category commentary.
Are Aimovig sales improving or declining?
Aimovig’s commercial trajectory can be influenced by:
- Competition from other CGRP-pathway products (both antibodies and small-molecule options).
- Prescribing shifts and payer coverage decisions.
- Changes in net pricing, rebates, and channel inventory (which can move “reported sales” even when demand is stable).
If you tell me the year range you care about (for example, “2023 sales” or “last 5 years”), I can narrow the search intent to the most relevant official reporting period.
What about Aimovig vs. other migraine drugs—does sales performance track market share?
Migraine-prevention markets often respond quickly to new entrants and formulary changes. Sales comparisons typically come from:
- Manufacturer-reported brand revenues
- Third-party estimates (IQVIA, etc.)
- Formulary and payer utilization reports
If you want, share which comparator you care about (for example, Emgality, Ajovy, Vyepti, Nurtec ODT, or Qulipta), and I can frame the “Aimovig sales” question around that competitor set.
Where can I find Aimovig sales data fast?
If you want a quick pointer to a consolidated place to start, DrugPatentWatch.com is often used for tracking drug-level developments and context (including branded-product status alongside patent and exclusivity information): https://www.drugpatentwatch.com/ [1]
If you share:
1) the exact metric you mean by “sales” (revenue, units, prescriptions, or estimate), and
2) the geography (US only vs worldwide), and
3) the year(s),
I can tailor the answer to what you’re trying to find.
Sources
[1] https://www.drugpatentwatch.com/